ClinicalTrials.gg
CompletedNCT04234217Updated Nov 2, 2026

Mechanisms of Prediabetic States in Sleep Apnea

An interventional study of Continuous positive airway pressure and Niacin in Sleep Apnea and Pre-diabetes, sponsored by University of Chicago. Completed at 1 site in United States. Open to participants aged 20 Years to 69 Years. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by University of Chicago · Not applicable, Interventional, and Other

How we know

Updated Nov 2, 2026Now CompletedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
20 Years to 69 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 369 studies in Sleep Apnea Syndromes with a site in United States — 49 open to participants now, 60 under way, 3 of them phase 3. Sleep Apnea Syndromes · United States.

Enrollment
197th of 284
35 · median 62
Started
2019
with 21 others
No phase
193 of 369
22 open now
Registered
266th of 369
by date

Among the 369 studies in Sleep Apnea Syndromes with a site in United States, this one is the 197th largest by enrollment of the 284 interventional ones that give a count, is one of 22 that started in 2019, is one of 193 with no phase, and was the 266th registered.

Sleep Apnea Syndromes

1,085 studies on the registry are indexed under Sleep Apnea Syndromes; 172 are open to participants now.

Browse Sleep Apnea Syndromes studies →

Open to participants now

49 of the 369 studies in Sleep Apnea Syndromes with a site in United States are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 119 Sleep Apnea Syndromes studies recruiting now, 58 (49%) set no upper age limit and 37 (31%) stop at 75 or younger; 25 take children under 18; 28 take healthy volunteers.

This study: 20 Years to 69 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 369 studies in Sleep Apnea Syndromes with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to better understand how sleep apnea contributes to the development of diabetes.

Read the detailed description

Substantial evidence indicates that obstructive sleep apnea (OSA) is associated with impaired glucose metabolism, however, metabolic mechanisms underlying this association remain unclear. This mechanistic study will determine systemic and cellular metabolic pathways that contribute to impaired glucose metabolism in obstructive sleep apnea (OSA). Understanding of how obstructive sleep apnea (OSA) affects glucose metabolism may help identify novel targets for risk prediction and/or treatment of metabolic impairments beyond continuous positive airway pressure (CPAP). Obstructive sleep apnea (OSA) patients with prediabetes will be studied under three in-laboratory conditions in a randomized cross-over design: untreated condition (obstructive sleep apnea), treated condition (continuous positive airway pressure), untreated but pharmacologically suppressed lipolysis condition (Niacin). The investigator will perform whole body and cellular assessments under each study condition.

03

Conditions studied

  • Sleep Apnea
  • Pre-diabetes

Keywords

  • Sleep
04

Who can participate

Ages eligible
20 Years to 69 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Overweight or obese
  • Prediabetic
  • Sleep apnea

Exclusion criteria

Exclusion Criteria:

  • Diabetic
  • Severe hypertension
  • Taking medications that can confound assessments
  • Any history of known bleeding disorders
  • Any underlying disease likely to limit life span or increase risk of intervention
  • Currently pregnant, trying to get pregnant or nursing
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • No intervention
    Untreated

    Untreated condition (obstructive sleep apnea)

  • Active comparator
    Continuous positive airway pressure (CPAP) treatment

    Continuous positive airway pressure (CPAP) treatment

    Device: Continuous positive airway pressure

  • Active comparator
    Niacin

    Untreated, pharmacological suppression of lipolysis by Niacin

    Other: Niacin

Interventions

  • DeviceContinuous positive airway pressure

    Continuous positive airway pressure (CPAP) treatment of obstructive sleep apnea (OSA)

    Also known as: CPAP

  • OtherNiacin

    Suppression of lipolysis by niacin infusion

    Also known as: Suppression of lipolysis by niacin infusion

06

What researchers measure

Primary outcomes

  1. Insulin Sensitivity

    Insulin sensitivity is calculated from a model fitted to blood glucose using insulin and C-peptide values measured during a glucose tolerance test

    Time frame: Untreated, within 4 months of screening

  2. Insulin Sensitivity

    Insulin sensitivity is calculated from a model fitted to blood glucose using insulin and C-peptide values measured during a glucose tolerance test

    Time frame: CPAP, within 4 months of screening

  3. Insulin Sensitivity

    Insulin sensitivity is calculated from a model fitted to blood glucose using insulin and C-peptide values measured during a glucose tolerance test

    Time frame: Niacin, within 4 months of screening

07

Study locations

1 site
  • University of Chicago
    Chicago, Illinois 60637, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2019 to primary completion in Jul 2026, 80 months.

Of 202 non-industry interventional studies with no phase under Sleep Apnea Syndromes, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 60. This study's 80 months is above that.

Counting every sponsor, half of 271 studies reached it within 26 months; a quarter within 11 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2019
First posted
Jan 21, 2020
StartActual
Nov 26, 2019
Primary completionActual
Jul 31, 2026
CompletionActual
Jul 31, 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 2, 2026
Primary completion
Jul 15, 2026→Jul 31, 2026 (actual)
Nov 2, 2026
Study completion
Jul 15, 2026→Jul 31, 2026 (actual)
Nov 2, 2026
Enrollment
300 (estimated)→35 (actual)
Nov 2, 2026
Eligibility
Maximum age 65 Years→69 Years
Nov 2, 2026
Primary outcomes
3 added, 3 removed
What changed in the outcomes
  • AddedInsulin SensitivityTime frame: Untreated, within 4 months of screening
  • AddedInsulin SensitivityTime frame: CPAP, within 4 months of screening
  • AddedInsulin SensitivityTime frame: Niacin, within 4 months of screening
  • RemovedPlasma norepinephrine levelsTime frame: Untreated, within 4 months of screening
  • RemovedPlasma norepinephrine levelsTime frame: CPAP, within 4 months of screening
  • RemovedPlasma norepinephrine levelsTime frame: Niacin, within 4 months of screening
Nov 2, 2026
Show all 1 update
  1. Nov 2, 2026
    Active, not recruiting→Completed
    Primary completion Jul 15, 2026→Jul 31, 2026 (now actual)
    Study completion Jul 15, 2026→Jul 31, 2026 (now actual)
    Enrollment 300 (estimated)→35 (actual)
    Eligibility Maximum age 65 Years→69 Years
    Primary outcomes 3 added, 3 removed
    What changed in the outcomes
    • AddedInsulin SensitivityTime frame: Untreated, within 4 months of screening
    • AddedInsulin SensitivityTime frame: CPAP, within 4 months of screening
    • AddedInsulin SensitivityTime frame: Niacin, within 4 months of screening
    • RemovedPlasma norepinephrine levelsTime frame: Untreated, within 4 months of screening
    • RemovedPlasma norepinephrine levelsTime frame: CPAP, within 4 months of screening
    • RemovedPlasma norepinephrine levelsTime frame: Niacin, within 4 months of screening
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04234217
Responsible party
Sponsor
First posted
Jan 21, 2020
Start date
Nov 26, 2019
Primary completion
Jul 31, 2026
Completion
Jul 31, 2026
Last update
Nov 2, 2026

Study contacts

Esra Tasali, MD
principal investigator · University of Chicago

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion